Dysregulation of glucose metabolism in HIV patients: Epidemiology, mechanisms, and management

Endocrine

Volumn 41, Issue 1, 2012, Pages 1-10

  Gutierrez, Absalon D ^a   Balasubramanyam, Ashok ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BEN TAUB GENERAL HOSPITAL   (United States)

Author keywords

Diabetes mellitus; Dysglycemia; HAART; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EXENDIN 4; FATTY ACID SYNTHASE; GLITAZONE DERIVATIVE; INDINAVIR; METFORMIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; PROTEINASE INHIBITOR; REPAGLINIDE; RITONAVIR; ROSIGLITAZONE; STAVUDINE; ZIDOVUDINE;

ACIDEMIA; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSGLYCEMIA; DYSLIPIDEMIA; FATTY LIVER; FLUID RETENTION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEART DEATH; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPOATROPHIC DIABETES MELLITUS; LIPOPROTEIN DEFICIENCY; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862642887     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9565-z     Document Type: Review

References (129)

1. I.J. Paik, D.P. Kotler, The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract. Res. Clin. Endocrinol. Metab. 25, 469-478 (2011)
2. W.M. El-Sadr et al., Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 6, 114-121 (2005) (Pubitemid 40425975)
3. F. Visnegarwala, L. Chen, S. Raghavan, E. Tedaldi, Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J. Infect. 50, 331-337 (2005) (Pubitemid 40533370)
4. P.C. Tien et al., Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21, 1739-1745 (2007) (Pubitemid 47237561)
5. C. Hadigan et al., Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32, 130-139 (2001) (Pubitemid 32150958)
6. T.T. Brown et al., Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179-1184 (2005) (Pubitemid 40720744)
7. M. Beregszaszi et al., Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J. Acquir. Immune Defic. Syndr. 40, 161-168 (2005) (Pubitemid 41395714)
8. R. Palacios et al., Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir. Ther. 11, 529-535 (2006) (Pubitemid 44024861)
9. S. De Wit et al., Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31, 1224-1229 (2008)
10. V. Estrada et al., Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 55, 940-945 (2006) (Pubitemid 43902897)
11. C. Jerico et al., Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28, 132-137 (2005) (Pubitemid 40095795)
12. M.E. Sobieszczyk et al., Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J. Acquir. Immune Defic. Syndr. 48, 272-280 (2008)
13. K. Samaras et al., Prevalence of metabolic syndrome in HIVinfected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30, 113-119 (2007) (Pubitemid 46052508)
14. K. Mondy et al., Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin. Infect. Dis. 44, 726-734 (2007)
15. C. Gazzaruso et al., Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J. Hypertens. 21, 1377-1382 (2003)
16. G. Meininger et al., Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51, 260-266 (2002) (Pubitemid 34168243)
17. C. Hadigan et al., Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virusinfected women. J. Clin. Endocrinol. Metab. 84, 1932-1937 (1999) (Pubitemid 30647012)
18. A.A. Howard et al., Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. 7, 389-396 (2006) (Pubitemid 44123250)
19. S.H. Mehta, R.D. Moore, D.L. Thomas, R.E. Chaisson, M.S. Sulkowski, The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 33, 577-584 (2003) (Pubitemid 36975845)
20. M.J. Glesby et al., Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study. Antivir. Ther. 15, 571-577 (2010)
21. F.A. Ramirez-Marrero et al., Prevalence of cardiometabolic risk factors in Hispanics living with HIV. Ethn. Dis. 20, 423-428 (2010)
22. S.L. Samson et al., Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp. Clin. Trials 27, 518-530 (2006) (Pubitemid 44635337)
23. A. Balasubramanyam et al., Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J. Clin. Endocrinol. Metab. 96, 2236-2247 (2011)
24. M. Mary-Krause et al., Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17, 2479-2486 (2003) (Pubitemid 38393320)
25. N. Friis-Moller et al., Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993-2003 (2003)
26. V.A. Triant, H. Lee, C. Hadigan, S.K. Grinspoon, Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506-2512 (2007) (Pubitemid 47037350)
27. S.W. Worm et al., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201, 318-330 (2010)
28. F. Magkos, C.S. Mantzoros, Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism 60, 749-753 (2011)
29. E.Y. Chan et al., Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. J. Virol. 81, 7571-7583 (2007) (Pubitemid 47047843)
30. S. Rasheed, J.S. Yan, A. Lau, A.S. Chan, HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study. PLoS One 3, e3003 (2008)
31. G. Aragones et al., Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. BMC Gastroenterol. 10, 92 (2010)
32. C. Grunfeld et al., Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90, 154-162 (1991)
33. C. Grunfeld et al., Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045-1052 (1992)
34. S. Das et al., In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 49, 538-542 (2006) (Pubitemid 43277877)
35. R.V. Sekhar et al., Metabolic basis of HIV-lipodystrophy syndrome. Am. J. Physiol. Endocrinol. Metab. 283, E332-E337 (2002) (Pubitemid 34827449)
36. P. Limone et al., Insulin resistance in HIV-infected patients: relationship with pro-inflammatory cytokines released by peripheral leukocytes. J. Infect. 47, 52-58 (2003) (Pubitemid 36850136)
37. S. Shrivastav et al., Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol. Endocrinol. 22, 234-247 (2008) (Pubitemid 351185928)
38. T. Kino, M. Mirani, S. Alesci, G.P. Chrousos, AIDS-related lipodystrophy/insulin resistance syndrome. Horm. Metab. Res. 35, 129-136 (2003) (Pubitemid 36577852)
39. P. Koutkia, K. Eaton, S.M. You, J. Breu, S. Grinspoon, Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. AIDS 20, 855-862 (2006) (Pubitemid 43731567)
40. C. Grady, M. Ropka, R. Anderson, H.C. Lane, Body composition in clinically stable men with HIV infection. J. Assoc. Nurses AIDS Care 7, 29-38 (1996)
41. V. Soriano et al., Antiretroviral drugs and liver injury. AIDS 22, 1-13 (2008) (Pubitemid 350301936)
42. D.A. Wohl et al., Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis. 43, 645-653 (2006) (Pubitemid 44267129)
43. J.S. Currier, D.V. Havlir, Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Top. HIV Med. 12, 31-45 (2004)
44. R.V. Sekhar et al., Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am. J. Clin. Nutr. 81, 1405-1410 (2005) (Pubitemid 41710245)
45. S.K. Gan et al., Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 51, 3163-3169 (2002) (Pubitemid 35246961)
46. G.M. Behrens et al., Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J. Clin. Invest. 110, 1319-1327 (2002) (Pubitemid 35285758)
47. J. Sutinen et al., Increased fat accumulation in the liver in HIVinfected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16, 2183-2193 (2002) (Pubitemid 35387273)
48. S.B. Haugaard et al., Insulin secretion in lipodystrophic HIVinfected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells. Am. J. Physiol. Endocrinol. Metab. 287, E677-E685 (2004) (Pubitemid 39237896)
49. T.T. Brown, K. Tassiopoulos, R.J. Bosch, C. Shikuma, G.A. McComsey, Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 33, 2244-2249 (2010)
50. G.F. de Larranaga, S.D. Wingeyer, L.M. Puga, B.S. Alonso, J.A. Benetucci, Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur. J. Clin. Microbiol. Infect. Dis. 25, 98-103 (2006) (Pubitemid 43333670)
51. M. Duong et al., Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C viruscoinfected patients undergoing antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 245-250 (2001) (Pubitemid 32661965)
52. A. Balasubramanyam, R.V. Sekhar, HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution. Res. Initiat. Treat. Action 12, 5-11 (2006)
53. C. Hadigan, J. Liebau, M. Torriani, R. Andersen, S. Grinspoon, Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J. Clin. Endocrinol. Metab. 91, 4438-4444 (2006) (Pubitemid 44833420)
54. B.H. McGovern et al., Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin. Infect. Dis. 43, 365-372 (2006) (Pubitemid 44078910)
55. M.S. Sulkowski et al., Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19, 585-592 (2005) (Pubitemid 40543981)
56. N. Crum-Cianflone et al., Nonalcoholic fatty liver disease among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 50, 464-473 (2009)
57. G.C. Farrell, C.Z. Larter, Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006)
58. A.E. Ogedegbe, D.L. Thomas, A.M. Diehl, Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect. Dis. 3, 329-337 (2003) (Pubitemid 36718011)
59. N. Stefan, H.U. Haring, The metabolically benign and malignant fatty liver. Diabetes 60, 2011-2017 (2011)
60. J.M. Schwarz et al., Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIVinfected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87, 942 (2002)
61. S. D'Amico et al., Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am. J. Clin. Nutr. 84, 204-211 (2006)
62. J.C. Lo et al., The effects of recombinant human growth hormone on body composition and glucose metabolism in HIVinfected patients with fat accumulation. J. Clin. Endocrinol. Metab. 86, 3480-3487 (2001) (Pubitemid 32761682)
63. D.P. Kotler et al., Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIVinfected patients. J. Acquir. Immune Defic. Syndr. 35, 239-252 (2004) (Pubitemid 38280649)
64. P. Koutkia, B. Canavan, J. Breu, S. Grinspoon, Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J. Clin. Endocrinol. Metab. 90, 2154-2160 (2005) (Pubitemid 40586255)
65. M.N. Rao et al., Effects of insulin-like growth factor (IGF)-I/ IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J. Clin. Endocrinol. Metab. 95, 4361-4366 (2010)
66. K.A. Lichtenstein et al., Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389-1398 (2001) (Pubitemid 32662290)
67. N. Gianotti et al., Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med. 12, 109-117 (2011)
68. A. Balasubramanyam, R.V. Sekhar, F. Jahoor, P.H. Jones, H.J. Pownall, Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Curr. Opin. Lipidol. 15, 59-67 (2004) (Pubitemid 39118019)
69. J.M. Lenhard et al., HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antivir. Res. 47, 121-129 (2000)
70. A.R. Miserez, P.Y. Muller, V. Spaniol, Indinavir inhibits sterolregulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 16, 1587-1594 (2002) (Pubitemid 34921103)
71. D. Nolan, M. John, S. Mallal, Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir. Ther. 6, 145-160 (2001) (Pubitemid 34016875)
72. S. Tsiodras, A. Perelas, C. Wanke, C.S. Mantzoros, The HIV-1/ HAART associated metabolic syndrome-novel adipokines, molecular associations and therapeutic implications. J. Infect. 61, 101-113 (2010)
73. G.S. Nagy et al., Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin. Infect. Dis. 36, 795-802 (2003) (Pubitemid 36337987)
74. J.L. Chan, K. Heist, A.M. DePaoli, J.D. Veldhuis, C.S. Mantzoros, The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 111, 1409-1421 (2003) (Pubitemid 36554712)
75. J.H. Lee, J.L. Chan, E. Sourlas, V. Raptopoulos, C.S. Mantzoros, Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91, 2605-2611 (2006) (Pubitemid 44024625)
76. K. Mulligan et al., The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J. Clin. Endocrinol. Metab. 94, 1137-1144 (2009)
77. T. Yamauchi et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002) (Pubitemid 35373562)
78. T. Yamauchi et al., Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003) (Pubitemid 36735700)
79. M. Iwaki et al., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52, 1655-1663 (2003) (Pubitemid 36792453)
80. L. Kosmiski, D. Kuritzkes, K. Lichtenstein, R. Eckel, Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir. Ther. 8, 9-15 (2003) (Pubitemid 36368298)
81. K. Falasca et al., Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann. Clin. Lab. Sci. 36, 59-66 (2006) (Pubitemid 43805880)
82. C. Vernochet et al., Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem. 280, 2238-2243 (2005)
83. C.L. Addy et al., Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 88, 627-636 (2003) (Pubitemid 36207802)
84. R. Verkauskiene et al., Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr. Res. 60, 225-230 (2006) (Pubitemid 44297598)
85. P.W. Hruz, Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract. Res. Clin. Endocrinol. Metab. 25, 459-468 (2011)
86. W. Lewis, B.J. Day, W.C. Copeland, Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2, 812-822 (2003) (Pubitemid 37361813)
87. C.M. Shikuma, L.J. Day, M. Gerschenson, Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr. Drug Targets Infect. Disord. 5, 255-262 (2005) (Pubitemid 41448371)
88. M. Gerschenson, K. Brinkman, Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 4, 763-777 (2004) (Pubitemid 39646821)
89. H. Murata, P.W. Hruz, M. Mueckler, The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275, 20251-20254 (2000) (Pubitemid 30457596)
90. H. Murata, P.W. Hruz, M. Mueckler, Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16, 859-863 (2002) (Pubitemid 34409009)
91. M.A. Noor et al., Metabolic effects of indinavir in healthy HIVseronegative men. AIDS 15, F11-F18 (2001) (Pubitemid 32424384)
92. M.A. Noor et al., Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16, F1-F8 (2002) (Pubitemid 34274457)
93. A. Carr, K. Samaras, D.J. Chisholm, D.A. Cooper, Abnormal fat distribution and use of protease inhibitors. Lancet 351, 1736 (1998)
94. A.K. Vyas, J.C. Koster, A. Tzekov, P.W. Hruz, Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J. Biol. Chem. 285, 36395-36400 (2010)
95. J.C. Koster, M.S. Remedi, H. Qiu, C.G. Nichols, P.W. Hruz, HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52, 1695-1700 (2003) (Pubitemid 36792459)
96. M.A. Noor, O.P. Flint, J.F. Maa, R.A. Parker, Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20, 1813-1821 (2006) (Pubitemid 44358899)
97. P.W. Hruz, Q. Yan, Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model. J. Acquir. Immune Defic. Syndr. 43, 624-625 (2006) (Pubitemid 44885632)
98. J.A. Aberg et al., Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49, 651-681 (2009)
99. M. Schambelan et al., Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31, 257-275 (2002) (Pubitemid 35278626)
100. D.M. Nathan et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009)
101. International Expert Committee, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334 (2009)
102. P.S. Kim et al., A1C underestimates glycemia in HIV infection. Diabetes Care 32, 1591-1593 (2009)
103. S.W. Worm et al., Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 119, 805-811 (2009)
104. A. Carr et al., Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288, 207-215 (2002) (Pubitemid 34755281)
105. A. Martin et al., Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18, 1029-1036 (2004) (Pubitemid 38591194)
106. G.A. McComsey et al., Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 38, 263-270 (2004) (Pubitemid 38113036)
107. A. Gavrila et al., Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin. Infect. Dis. 36, 1593-1601 (2003) (Pubitemid 36783345)
108. K.E. Yarasheski et al., Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90, 133-138 (2001) (Pubitemid 32038513)
109. K.V. Fitch et al., Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20, 1843-1850 (2006) (Pubitemid 44358902)
110. E.S. Engelson et al., Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism 55, 1327-1336 (2006) (Pubitemid 44354946)
111. J.B. Albu, C.M. Kim, E.S. Engelson et al., Effects of diet and exercise and/or rosiglitazone on body composition and glucose metabolism in HIV+ and HIV- subjects. Antivir. Ther. 13(Suppl. 4), A31 (2008)
112. T. Saint-Marc, J.L. Touraine, Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13, 1000-1002 (1999) (Pubitemid 29240202)
113. C. Hadigan et al., Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 86, 939-943 (2001) (Pubitemid 32207521)
114. Lactic Acidosis International Study Group, Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 21, 2455-2464 (2007)
115. L.T. Matthews et al., A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. PLoS One 6, e18736 (2011)
116. C. Hadigan et al., Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 140, 786-794 (2004)
117. J. Sutinen et al., Rosiglitazone in the treatment of HAARTassociated lipodystrophy-a randomized double-blind placebocontrolled study. Antivir. Ther. 8, 199-207 (2003) (Pubitemid 36960893)
118. A. Carr et al., No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363, 429-438 (2004) (Pubitemid 38210059)
119. J. Sutinen, The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res. 2009, 373524 (2009)
120. S.E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007) (Pubitemid 46919772)
121. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. http://www.fda.gov/Drugs/ DrugSafety/ucm255005.htm (2011). Accessed 4 November 2011
122. A.M. Lincoff, K. Wolski, S.J. Nicholls, S.E. Nissen, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188 (2007) (Pubitemid 47403104)
123. S.H. Sheth, R.J. Larson, The efficacy and safety of insulinsensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect. Dis. 10, 183 (2010)
124. L. Slama et al., Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir. Ther. 13, 67-76 (2008) (Pubitemid 351541675)
125. A. Gavrila et al., Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 9 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin. Infect. Dis. 40, 745-749 (2005) (Pubitemid 40381352)
126. R.W. Nesto et al., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108, 2941-2948 (2003) (Pubitemid 37517824)
127. P. Oriot, M.P. Hermans, P. Selvais, M. Buysschaert, X. de la Tribonniere, Exenatide improves weight loss insulin sensitivity and beta-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann. Endocrinol. (Paris) 72, 244-246 (2011)
128. M. Briones, M. Bajaj, Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin. Pharmacother. 7, 1055-1064 (2006) (Pubitemid 43949943)
129. J.D. Lundgren et al., European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9, 72-81 (2008) (Pubitemid 351232645)